These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
763 related articles for article (PubMed ID: 8408645)
1. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. Wetzler M; Talpaz M; Van Etten RA; Hirsh-Ginsberg C; Beran M; Kurzrock R J Clin Invest; 1993 Oct; 92(4):1925-39. PubMed ID: 8408645 [TBL] [Abstract][Full Text] [Related]
2. Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients. Maxwell SA; Kurzrock R; Parsons SJ; Talpaz M; Gallick GE; Kloetzer WS; Arlinghaus RB; Kouttab NM; Keating MJ; Gutterman JU Cancer Res; 1987 Mar; 47(6):1731-9. PubMed ID: 2434223 [TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840 [TBL] [Abstract][Full Text] [Related]
5. [Molecular analysis of transformation into blast crisis in chronic myelogenous leukemia]. Okabe M Hokkaido Igaku Zasshi; 1993 Mar; 68(2):237-50. PubMed ID: 8509066 [TBL] [Abstract][Full Text] [Related]
6. KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts. Andersson BS; Collins VP; Kurzrock R; Larkin DW; Childs C; Ost A; Cork A; Trujillo JM; Freireich EJ; Siciliano MJ Leukemia; 1995 Dec; 9(12):2100-8. PubMed ID: 8609723 [TBL] [Abstract][Full Text] [Related]
7. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536 [TBL] [Abstract][Full Text] [Related]
8. Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia. Cuenco GM; Ren R Oncogene; 2001 Dec; 20(57):8236-48. PubMed ID: 11781838 [TBL] [Abstract][Full Text] [Related]
9. Stage- and lineage-specific expression of the HOXA10 homeobox gene in normal and leukemic hematopoietic cells. Lawrence HJ; Sauvageau G; Ahmadi N; Lopez AR; LeBeau MM; Link M; Humphries K; Largman C Exp Hematol; 1995 Oct; 23(11):1160-6. PubMed ID: 7556525 [TBL] [Abstract][Full Text] [Related]
10. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein. Gotoh A; Miyazawa K; Ohyashiki K; Tauchi T; Boswell HS; Broxmeyer HE; Toyama K Exp Hematol; 1995 Oct; 23(11):1153-9. PubMed ID: 7556524 [TBL] [Abstract][Full Text] [Related]
11. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063 [TBL] [Abstract][Full Text] [Related]
12. [The cellular and molecular-biological studies on Philadelphia chromosome-positive acute lymphocytic leukemia]. Kunieda Y Hokkaido Igaku Zasshi; 1993 May; 68(3):337-49. PubMed ID: 8319933 [TBL] [Abstract][Full Text] [Related]
13. Two bcr/abl fusion gene products, P210bcr/abl and P190bcr/abl, are equally sensitive to the protein tyrosine phosphatase of mature granulocytes. Nishimura J; Okamura J; Shibata K; Takahira H; Yufu Y; Kato S; Hirata J; Umemura T; Nawata H Int J Hematol; 1991 Dec; 54(6):471-8. PubMed ID: 1793829 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Gambacorti-Passerini C; le Coutre P; Mologni L; Fanelli M; Bertazzoli C; Marchesi E; Di Nicola M; Biondi A; Corneo GM; Belotti D; Pogliani E; Lydon NB Blood Cells Mol Dis; 1997 Dec; 23(3):380-94. PubMed ID: 9446752 [TBL] [Abstract][Full Text] [Related]
15. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model. Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059 [TBL] [Abstract][Full Text] [Related]
16. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Okuda K; Golub TR; Gilliland DG; Griffin JD Oncogene; 1996 Sep; 13(6):1147-52. PubMed ID: 8808688 [TBL] [Abstract][Full Text] [Related]
17. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization. Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246 [TBL] [Abstract][Full Text] [Related]
19. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Beran M; Pisa P; O'Brien S; Kurzrock R; Siciliano M; Cork A; Andersson BS; Kohli V; Kantarjian H Cancer Res; 1993 Aug; 53(15):3603-10. PubMed ID: 8339266 [TBL] [Abstract][Full Text] [Related]